The creation of oral insulin has been no simple task. "People have been dreaming about oral insulin since 1922," Dr. Ki…
Oral Insulin
Mannkind Confirms Studies using Afrezza Insulin Threapy
MannKind Corporation announced that it has confirmed with the U.S. Food and Drug Administration the design of two clinic…
Inhaled Insulin, Afrezza, Does Not Increase Cardiovascular Risk
Treating type 1 and type 2 diabetes with investigational ultra rapid acting mealtime insulin Afrezza (insulin human [rDN…
FDA Rejects Afrezza, Mannkind’s Inhaled Insulin
The FDA's Center for Drug Evaluation and Research has issued a complete response letter to Mannkind corp. regarding the …
Biocon Oral Insulin Shows Promise in Type 2 Diabetes Patients
Biocon Ltd., India's largest biotechnology company, released preliminary data from a recently concluded clinical study c…
Positive Results for Oral Insulin Delivery in Pre-Clinical Trials
MonoSol Rx and Midatech Group Ltd. anounced positive results from pre-clinical proof-of-concept studies for oral insulin…
FDA Informs Mannkind It Needs More Time to Review AFREZZA NDA
The FDA informed MannKind Corporation that it would not be able to complete the review of the New Drug Application (NDA)…
Novo Nordisk to Develop Oral Insulin
Novo Nordisk has announced the signing of an exclusive Development and Licence Agreement with Emisphere Technologies, In…
MannKind Presents New Data on Novel Device Technology at Diabetes Technology Conference
MannKind Corporation representatives at the 10th annual meeting of the Diabetes Technology Society unveiled new data on …
FDA Accepts AFREZZA Complete Response Resubmission and Sets Target Action Date
MannKind Corporation announced that it has submitted, and the U.S. Food and Drug Administration (FDA) has accepted, Mann…
